Search HRMY
Harmony Biosciences Holdings, Inc.
Nasdaq · CIK 1802665
Last close39.64
Daily change+0.07 (0.18%)
10 Years gain+7.11%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
HRMY · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
77.3Momentum
44.0Acceleration
44.0Confidence
86.0Annual Revenue7
Quarterly Revenue25
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth23.2 / 25
Quality15.2 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 3.1715 percentage points.
Key Metrics
Revenue Growth TTM31.28%OK
Revenue CAGR 3Y25.64%OK
Gross Margin77.58%OK
Operating Margin26.21%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC43.62%OK
Incremental Operating Margin 3Y34.2%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.39%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $868.45M | $670.11M | $208.47M | $348.20M | $347.89M | 77.16% | 24% | 40.06% | 48.85% | 58.54M |
| 2025 FY Dec 31, 2024 | $714.73M | $557.92M | $190.83M | $219.82M | $218.67M | 78.06% | 26.7% | 30.59% | 42.68% | 57.87M |
| 2025 FY Dec 31, 2023 | $582.02M | $460.79M | $192.03M | $219.39M | $219.08M | 79.17% | 32.99% | 37.64% | 49.34% | 60.37M |
| 2024 FY Dec 31, 2022 | $437.86M | $354.37M | $120.19M | $144.47M | $144.29M | 80.93% | 27.45% | 32.95% | 37.6% | 61.1M |
| 2023 FY Dec 31, 2021 | $305.44M | $249.92M | $87.53M | $98.56M | $98.26M | 81.82% | 28.66% | 32.17% | 78.18% | 59.21M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $916.61M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-090090, 0001104659-25-105962 |
| Revenue Growth TTM | 31.28% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-090090, 0001104659-25-105962 |
| Revenue CAGR 3Y | 25.64% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-018859 |
| Revenue CAGR 5Y | 40.3% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-018859 |
| Gross Profit CAGR 3Y | 23.66% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-018859 |
| Operating Income Growth | 25.57% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001104659-26-090090, 0001104659-25-105962 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 77.58% | Gross Profit / Revenue | OK | 0001104659-26-090090, 0001104659-25-105962 |
| Operating Margin | 26.21% | Operating Income / Revenue | OK | 0001104659-26-090090, 0001104659-25-105962 |
| ROIC | 43.62% | NOPAT / Average Invested Capital | OK | 0001104659-26-090090, 0001104659-25-105962 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-090090 |
| Current Ratio | 3.48x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 4.34x | (Cash + Short-term Investments) / Total Debt | OK | 0001104659-26-090090 |
| Revenue per Diluted Share | $15.60 | Revenue / Diluted Shares | OK | 0001104659-26-090090, 0001104659-25-105962 |